Aggressive Growth Consolidates Dendrite Leadership in China; Bayer Deploys Dendrite Solution Ahead of Time and on Budget.Business Editors/Health & Medical Writers MORRISTOWN, N.J.--(BUSINESS WIRE)--Feb. 5, 2002 Dendrite dendrite: see nervous system; synapse. (NASDAQ/NMS: DRTE DRTE Defence Research Telecommunications Establishment ) today announced continuing rapid expansion of its pharmaceutical support operations in China. Dendrite, the first and leading company offering pharmaceutical sales technology in China, recently completed a seamless rollout of its Medicheck(TM) system for Bayer China. Enabling drug companies to maximize the productivity and effectiveness of their sales forces, Medicheck(TM) is a version of Dendrite's WebForce(TM) sales technology product suite designed for the specific requirements of pharmaceutical companies conducting business in China. Currently, more than 800 drug reps drug 'rep' Pharmaceutical industry A drug company employee who has regular contact with prescribing physicians; DRs provide details on the proper administration of new agents, and usually try to have the physician change prescribing practices in favor of the DR are using Dendrite's Medicheck(TM) solution in China. Dendrite, which also serves the sales force requirements of Eli Lilly Eli Lilly can refer to:
"Dendrite's solutions are cost-effective and designed for China's unique market needs," said JP Modde, Vice President, Asia/Pacific. "Bayer China selected Dendrite for its deep regional industry knowledge and technical expertise to assist in driving the productivity of its sales and marketing efforts. With the Chinese pharmaceutical market projected to grow between 7% and 10% annually over the next five years, we look forward to helping companies take advantage of the tremendous opportunity this market presents." Dendrite opened a Representative Office in Shanghai in October 2001 to begin service to China's growing pharmaceutical industry. It offers a broad range of services--including product and customer support--for both Chinese and international drug manufacturers operating in that country. Dendrite also recently sponsored and chaired the Second Annual China Pharmaceutical Executive Forum, the leading pharmaceutical conference in China. Dendrite led discussions on how drug manufacturers can implement winning strategies to succeed in China's pharmaceutical industry. It attracted leading pharmaceutical companies such as Merck Sharp & Dhome, AstraZeneca, GlaxoSmithKline, Baxter, and Pharmacia; top Chinese drug manufacturers; and the country's State Drug Administration. About Dendrite Dendrite, the visionary innovator in global pharmaceutical technology, helps clients strategically manage customer relationships to increase market share. The company creates unique, analytically an·a·lyt·ic or an·a·lyt·i·cal adj. 1. Of or relating to analysis or analytics. 2. Dividing into elemental parts or basic principles. 3. driven solutions that enable pharmaceutical companies to influence prescriber pre·scribe v. pre·scribed, pre·scrib·ing, pre·scribes v.tr. 1. To set down as a rule or guide; enjoin. See Synonyms at dictate. 2. To order the use of (a medicine or other treatment). behavior, thereby delivering a sustained competitive advantage. More than 80,000 pharmaceutical sales representatives pharmaceutical sales representative Detailer, Drug rep Drug industry A drug company employee who regularly visits physicians and office practices, providing information on the company's products–usually putting a negative 'spin' on competitors' products. See Detailing. and their managers from over 150 companies and 57 countries use Dendrite products and services. They represent 19 of the top 20 pharmaceutical companies. For more information, visit www.dendrite.com. Note: Dendrite is a registered trademark of Dendrite International, Inc. The foregoing contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. within the meaning of The Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The statements may be identified by such forward-looking terminology as "expect," "believe," "may," "will," "intend," "plan," and similar statements or variations. Such forward-looking statements are based on our current estimates and assumptions and involve certain significant risks and uncertainties, including: risks associated with and dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy selling cycles, product implementation cycles, customer budget cycles, and timing of revenue recognition; dependence on major customers; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; retention of key senior managers; and unique characteristics of the consumer packaged goods Noun 1. packaged goods - groceries that are packaged for sale foodstuff, grocery - (usually plural) consumer goods sold by a grocer plural, plural form - the form of a word that is used to denote more than one industry. Other important factors that should be considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion